Apogee Q3 net loss $20.8M; cash $422.9M; APG777 Phase 1 dosed ahead of schedule

Apogee Therapeutics, Inc.

2023-Q3 EPS reported -$3.04

Net loss $20.8M in Q3 2023 vs $19.7M in Q3 2022; R&D spend rose to $17.1M from $9.9M.
Cash $422.9M as of Sept 30, 2023; expected runway into Q4 2026 after $345M IPO in July.
Phase 1 trial of APG777 begun ahead of schedule; initial PK/safety data from healthy volunteers expected mid-2024.
Development candidate for APG808 (anti-IL-4Rα) finalized in Q4 2023; preclinical half-life up to 26 days vs 12 days for DUPIXENT.
Mark C. McKenna appointed Chairman; Matt Batters joined as General Counsel in August 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Apogee Therapeutics, Inc. reported financial results for the quarter ended September 30, 2023.

Period: the quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 13, 2023, Apogee Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

Apogee Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-116703

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.